Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Thomas S Y, Chan"'
Autor:
Harinder Gill, Rita Yim, Herbert H. Pang, Paul Lee, Thomas S. Y. Chan, Yu‐Yan Hwang, Garret M. K. Leung, Ho‐Wan Ip, Rock Y. Y. Leung, Sze‐Fai Yip, Bonnie Kho, Harold K. K. Lee, Vivien Mak, Chi‐Chung Chan, June S. M. Lau, Chi‐Kuen Lau, Shek‐Yin Lin, Raymond S. M. Wong, Wa Li, Edmond S. K. Ma, Jun Li, Gianni Panagiotou, Joycelyn P. Y. Sim, Albert K. W. Lie, Yok‐Lam Kwong
Publikováno v:
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020)
Abstract Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 in
Externí odkaz:
https://doaj.org/article/2744c5249b7a4f84a43188e34f729a01
Autor:
Desmond Y H Yap, Davina Lie, Tiffany Lau, Alex Tang, Gavin Chan, Thomas S Y Chan, Joycelyn Sim, Albert K W Lie, Tak Mao Chan
Publikováno v:
Clinical Kidney Journal. 16:976-984
Background Various glomerular pathologies have been reported in patients who have undergone haematopoietic stem cell transplantation (HSCT), but the data on clinico-pathological correlations and clinical outcome remain limited. Methods We analysed th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a980b21b041ccc8fa6c336a0d39d1e01
https://doi.org/10.1093/ckj/sfac264
https://doi.org/10.1093/ckj/sfac264
Autor:
Thomas S. Y. Chan, Albert K. W. Lie, Joycelyn P Y Sim, Eric Tse, Yok-Lam Kwong, Garret M. K. Leung, Yu-Yan Hwang
Publikováno v:
Annals of Hematology. 101:155-163
Graft-versus-host disease (GVHD) is an important complication after allogeneic haematopoietic stem cell transplantation (HSCT). Corticosteroids are the standard first-line treatment. Steroid-resistant/-dependent (SR/D) acute and chronic GVHD (aGVHD,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4c34967180ce2e0f1af6ad1aa97f723
https://doi.org/10.1007/s00277-021-04658-x
https://doi.org/10.1007/s00277-021-04658-x
Autor:
Thomas S. Y. Chan, Chi Yan Wong, Harinder Gill, Ho Yan Au, Kwok Ying Chan, Kwok Wai Tsang, Cho Wing Li, Chun Him Hui
Publikováno v:
Annals of Palliative Medicine. 10:6316-6324
Background Evidence showed that early palliative care could have many benefits in clinical outcomes for patients living with advanced medical illnesses. In fact, most of these studies have not involved patients with advanced haematologic cancer (HC),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718cd8d103500b94c41f9bdbbc007df5
https://doi.org/10.21037/apm-21-276
https://doi.org/10.21037/apm-21-276
Autor:
Thomas S. Y. Chan, Danny Chung Hsu, Yok-Lam Kwong, Suk Hyun Kang, Wei-Ting Chen, Rene Wing-Yan Chau, Adnan Alsumali, Sally Shuk Yee Cheng
Publikováno v:
Journal of Medical Economics. 23:1485-1492
The cost-effectiveness of letermovir as cytomegalovirus (CMV) prophylaxis in adult seropositive patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), compared with the conventional strategy of preemptive treatment, has not be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee68c134b8dd88531b6bab805b9822b
https://doi.org/10.1080/13696998.2020.1843321
https://doi.org/10.1080/13696998.2020.1843321
Autor:
Eric Tse, Yok-Lam Kwong, Thomas S. Y. Chan, Yu-Yan Hwang, Chor Sang Chim, Anskar Y.H. Leung, Pek-Lan Khong
Publikováno v:
Hematological Oncology. 38:726-736
The efficacy and safety of low-dose anti-PD1 antibodies in relapsed/refractory classical Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks, Q3W) or nivolumab (40 mg Q2W) were administered to patients with relapsed/refra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30833b67642c396478929eb1aa57f7f5
https://doi.org/10.1002/hon.2787
https://doi.org/10.1002/hon.2787
Autor:
Vikneswari Rajasegaran, Chee Leong Cheng, Junhun Cho, Lay Poh Khoo, Huangming Hong, Daryl Tan, Daryl Ming Zhe Cheah, Dachuan Huang, Rou-Jun Peng, Jeslin Chian Hung Ha, Jing Quan Lim, Yeow Tee Goh, Burton Kuan Hui Chia, Seok Jin Kim, Tiffany Tang, Olaf Rötzschke, Eric Tse, Choon Kiat Ong, Won Seog Kim, Maarja-Liisa Nairismagi, Yok-Lam Kwong, Qingqing Cai, Colin Phipps, Yurike Laurensia, Jing Tan, Yvonne Loh, Jin-Xin Bei, Soon Thye Lim, Tongyu Lin, Benjamin Mow, Qi-Chun Cai, Johnathan Xiande Lim, Rex Au-Yeung, Cedric Chuan Young Ng, Esther Kam Yin Wong, Thomas S. Y. Chan, Li-Mei Poon, Jason Yongsheng Chan, Nicholas Francis Grigoropoulos, Jabed Iqbal, William Hwang
Publikováno v:
Leukemia. 34:3413-3419
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73bb690d267f2d46a2bd3b2eaf660cbf
https://doi.org/10.1038/s41375-020-1000-0
https://doi.org/10.1038/s41375-020-1000-0
Publikováno v:
Annals of Hematology. 99:2949-2952
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cbe99faf3db27feb14bd51d17d00a19
https://doi.org/10.1007/s00277-020-04110-6
https://doi.org/10.1007/s00277-020-04110-6
Publikováno v:
Expert Review of Hematology. 13:471-480
Introduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0576dbb03cd5197526c42a3166eb5e15
https://doi.org/10.1080/17474086.2020.1751608
https://doi.org/10.1080/17474086.2020.1751608
Autor:
Gianni Panagiotou, Thomas S. Y. Chan, Paul P. Lee, Bonnie Kho, Sze-Fai Yip, Chi-Kuen Lau, Wa Li, Herbert Pang, Vivien Mak, Joycelyn Sim, Edmond S. K. Ma, Yok-Lam Kwong, Harold K. K. Lee, Rita Yim, Ho-Wan Ip, Raymond S.M. Wong, Albert K. W. Lie, Shek‐Yin Lin, Harinder Gill, June S. M. Lau, Jun Li, Chi-Chung Chan, Yu-Yan Hwang, Rock Y. Y. Leung, Garret M. K. Leung
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020)
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020)
Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 induction a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e1b9bb7e961ef53889aeaa1c979d54
http://europepmc.org/articles/PMC7221314
http://europepmc.org/articles/PMC7221314